Table 16 Top 10 pairs of drugs with their correlation with subtype 4 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Pregnenolone | Bromocriptine | − 0.99 | − 0.42 | − 0.40 | 1 | 24 | 38 |
EDTA | EMD-1214063 | − 0.69 | − 0.46 | − 0.35 | 2 | 8 | 81 |
Maraviroc | Pregnenolone | − 0.68 | − 0.46 | − 0.42 | 3 | 9 | 24 |
Rupatadine | TG-100801 | − 0.68 | − 0.58 | − 0.37 | 4 | 1 | 60 |
Maraviroc | TG-100801 | − 0.67 | − 0.46 | − 0.37 | 5 | 9 | 60 |
Finasteride | Emtricitabine | − 0.66 | − 0.43 | − 0.37 | 6 | 19 | 68 |
Maraviroc | Tadalafil | − 0.66 | − 0.46 | − 0.35 | 7 | 9 | 89 |
Dofequidar | Triflupromazine | − 0.66 | − 0.44 | − 0.36 | 8 | 14 | 78 |
Dofequidar | PF-04620110 | − 0.66 | − 0.44 | − 0.38 | 9 | 14 | 55 |
Dofequidar | Finasteride | − 0.65 | − 0.44 | − 0.43 | 10 | 14 | 19 |